Skip to main content

Table 4 Adjusted Hazard ratio of breast cancer survival

From: Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival

 

Model 1 (5-subgrouping)

Model 2 (4-subgrouping)

Variables

Disease-free survival

Overall survival

Disease-free survival

Overall survival

 

HR (95%CI)

P-value

HR (95%CI)

P-value

HR (95%CI)

P-value

HR (95%CI)

P-value

Molecular subtyping

        

   IHC-Luminal A

    

1.00

 

1.00

 

   IHC-Luminal B

    

1.48 (1.04-2.09)

0.027

1.86 (1.11-3.11)

0.018

   IHC-HER2

    

1.60 (1.11-2.31)

0.011

3.07 (1.86-4.87)

< 0.001

   IHC-TNBC

    

1.19 (0.89-1.68)

0.293

2.91 (1.88-4.48)

< 0.001

Molecular subtyping

        

   IHC-Luminal A

1.00

 

1.00

     

   IHC-Luminal B

1.48 (1.04-2.09)

0.028

1.86 (1.11-3.11)

0.018

    

   IHC-HER2

1.60 (1.11-2.31)

0.012

3.07 (1.86-4.87)

< 0.001

    

   IHC-BLBC

1.03 (0.68-1.56)

0.874

2.80 (1.68-4.68)

< 0.001

    

   IHC-QNBC/5NP

1.43 (0.93-2.18)

0.102

3.04 (1.75-5.26)

< 0.001

    

Tumor size (cm)

        

   ≤ 2 cm

1.00

 

1.00

 

1.00

 

1.00

 

   2-5 cm

1.39 (1.06-1.86)

0.02

2.26 (1.46-3.50)

< 0.001

1.39 (1.05-1.85)

0.021

2.26 (1.46-3.39)

< 0.001

   > 5cm

2.19 (1.44-3.36)

< 0.001

3.21 (2.13-4.67)

< 0.001

2.16 (1.42-3.32)

< 0.001

3.19 (1.78-5.73)

< 0.001

LN involvement

        

   Negative

1.00

 

1.00

 

1.00

 

1.00

 

   Positive

2.40 (1.82-3.16)

< 0.001

3.17 (2.14-4.61)

< 0.001

2.41 (1.83-3.18)

< 0.001

3.17 (2.14-4.61)

< 0.001

Adjuvant Chemotherapy

        

   Not done

1.00

 

1.00

 

1.00

 

1.00

 

   Done

0.70 (0.50-0.99)

0.049

0.34(0.22-0.50)

< 0.001

0.70 (0.50-0.99)

0.048

0.34 (0.22-0.50)

< 0.001

  1. IHC: immunohistochemistry